This analysis examines the historical and forecast performance for Sanofi-Aventis in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

Analysis of Pfizer’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Watson in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales

This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

Analysis of Genzyme’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

Analysis of Abbott’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Shionogi in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales f

Analysis of Schering-Plough’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 yea

This analysis examines the historical and forecast performance for Ipsen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales

This analysis examines the historical and forecast performance for Chugai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

Analysis of Roche’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. An interactive data

This analysis examines the historical and forecast performance for Cephalon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

This analysis examines the historical and forecast performance for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales

Analysis of Bayer Schering Pharma’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Merck & Co. in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

Analysis of Bristol-Myers Squibb’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales f

This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

Analysis of Celgene’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Eisai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales

Analysis of Boehringer Ingelheim’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

Analysis of AstraZeneca’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal